Core Viewpoint - CytomX Therapeutics, Inc. has announced an underwritten offering of 76,923,076 shares of its common stock at a price of $1.30 per share, aiming to raise approximately $100 million in gross proceeds before expenses [1][2]. Group 1: Offering Details - The offering is expected to close on May 13, 2025, subject to customary closing conditions [1]. - The net proceeds from the offering will be utilized for research and development, general corporate purposes, and working capital needs [2]. - The offering is led by Longitude Capital, with participation from several investment firms including OrbiMed and Venrock Healthcare Capital Partners [2]. Group 2: Company Overview - CytomX is a clinical-stage biopharmaceutical company focused on developing conditionally activated biologics for cancer treatment [6]. - The company’s pipeline includes therapeutic candidates such as CX-2051, a masked ADC targeting EpCAM, and CX-801, a masked interferon alpha-2b PROBODY cytokine [6]. - CytomX has established collaborations with major oncology leaders including Amgen and Bristol Myers Squibb [6].